Former federal prosecutor Doug Burns on the DOJ’s indictment of FedEx over prescription drug shipments.
Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.
High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...
Valeant Pharmaceuticals Inc won't pay whatever it takes to acquire rival Allergan Inc, and it will not turn its bid into an all-cash deal, Valeant Chief Executive Mi...
Novartis (NYSE:NVS) is revamping its portfolio with a flurry of deals worth about $25 billion, as the Swiss pharmaceutical giant plans to swap assets with GlaxoSmith...
FBN’s Lauren Simonetti with the latest on the market.
Strategas Research Partners CIO Jason Trennert and Philadelphia Trust Company CEO Michael Crofton on the M&A market for pharmaceutical and biotech companies.
In the world of drug development, collaboration is key.When Kathy Giusti was diagnosed with a rare and fatal blood cancer nearly 20 years ago, there wasn't a single ...
Acorda Therapeutics CEO Ron Cohen gives insider perspective on his company’s success and the recent biotech selloff.
GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company alread...
Mayo Clinic CEO Dr. John Noseworthy and American Action Forum president Douglas Holtz-Eakin discuss health-care spending.
U.S. Trust chief investment officer Chris Hyzy gives tips for investing.
When it comes to matters of the heart, people often respond with a gut reaction rather than a well-thought-out plan of action.When Ilan Ganot, a banker at JPMorgan C...
‘Unstoppable’ author Ralph Nader on the mounting General Motors recall scandal.
FBN’s Liz MacDonald on companies with massive overseas cash piles.
The Goldwater Institute’s Lucy Caldwell on the ‘Right to Try’ legislation.
MDC Partners CEO Miles Nadal on the collapse of the Omnicom-Publicis deal.
Schaefer’s Investment Research senior equity analyst Joe Bell and Bryn Mawr Trust CIO Ernie Cecilia on LinkedIn and other stocks to invest in.
Stossel and guest discuss how government uses its force to push people around and take their stuff
FNC Medical A-Team’s Dr. Marc Siegel on the MRSA Superbug, Ebola and a second wave of the Flu hitting the Northeastern U.S.